Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 14Neoplasm Metastasis 5Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

trifluridine tipiracil drug combination 1tipiracil 1pembrolizumab 1cabozantinib 1andecaliximab 1Trifluridine 1S 1 (combination) 1Oxaliplatin 1Nivolumab 1Irinotecan 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastric Adenocarcinoma × trifluridine tipiracil drug combination × Clear all
NCT04074343 2024-02-02

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

University of California, Irvine

Phase 1 Completed
20 enrolled 9 charts
Gastrointestinal

Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡